NanoViricides, Inc.
New York Stock Exchange ArcaCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Anil R. Diwan
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1 Controls Drive Shelton CT United States of America 06484
- IPO Date
- Oct 26, 2005
- CIK
- 0001379006
- Website
- nanoviricides.com
- Similar Companies
- Business
- NanoViricides, Inc. (NNVC) is a clinical-stage nano-biopharmaceutical company that discovers, develops and commercializes nanoviricide-class antiviral therapeutics designed to mimic human cell receptors and trap viruses for destruction; its proprietary platform technology, licensed from TheraCour Pharma, Inc., targets viruses including RSV, COVID-19/SARS-CoV/MERS coronaviruses, influenza/bird flu, MPOX/smallpox, shingles (VZV), HSV-1/HSV-2 cold sores/genital lesions, HIV (potential functional cure), Ebola/Marburg hemorrhagic viruses, dengue, rabies, hepatitis C and others. The company operates its own multi-kilogram-scale cGMP-compliant manufacturing facility in Shelton, Connecticut, where it was founded in 2005 as the top public entity above private IP-holding firms TheraCour Pharma and AllExcel; it serves global markets with a focus on life-threatening viral infections and advances candidates through human clinical trials. Its lead product, NV-387, a broad-spectrum antiviral, completed Phase I trials and advances toward Phase II for RSV, COVID/Long COVID, influenza, respiratory infections and MPOX/smallpox, including orphan drug strategy via a December 2025 master services agreement with OnlyOrphansCote and planned Phase II in the Democratic Republic of Congo; NV-HHV-1 targets shingles/chickenpox/HSV rashes as a dermal cream, while earlier-stage assets include NV-HIV-1, NV-CoV-2 and NV-CoV-2-R (remdesivir-encapsulating version). Recent developments include a $6 million registered direct offering closed in November 2025 to fund clinical progression, quarterly cash burn of $1.59 million as of September 2025 with a $3 million management loan facility, non-dilutive funding pursuits, presentations at the 2025 Pharma Partnering Summit, and a fortified fiscal position post-annual reporting.
Company News
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials
Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
NanoViricides (NYSE:NNVC) Trading Down 2.2% – Time to Sell?
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo